drugset / Trial / NCT04730544
Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC.
Phase 2
Active not recruiting
96 enrolled
GERCOR - Multidisciplinary Oncology Cooperative Group
Bristol-Myers Squibb · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
NIPISAFE is open-label, phase II study to identify a combination scheme of nivolumab and ipilimumab with a high level of clinical activity, but with a lower toxicity in MSI/dMMR metastatic colorectal cancer patients.
Timeline
- Start
- 2021-05-21
- Primary completion
- 2027-04
- Completion
- 2028-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | 1 mg/kg | — |
| Subject | Nivolumab | Monoclonal antibody | 480 mg | — |